CheckMate 649 3-Year Follow-up: Nivolumab Plus Chemotherapy for Gastric and Esophageal Cancers

CheckMate 649: nivolumab and chemotherapy or ipilimumab in GC/GEJC/EAC

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC

Checkmate 649 | Out now on Plenary Session Podcast feed

Emerging Biomarkers and Novel Therapies for Esophageal Cancer

Overview of gastroesophageal cancer

Gastroesophageal Cancer: Current Positioning of Immunotherapy

Immune Checkpoint Inhibitor Therapy for Locally Advanced and Early-Stage Esophageal/GEJ Cancer

September 26, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

Checkpoint Inhibition in GI Cancers: Recent Advances and Their Application in Clinical Practice

5th PSMMC immune-oncology Meeting (PIOM)

Management of Esophageal/GEJ Cancers: An Interdisciplinary Tumor Board on Adjuvant Immunotherapy

進行胃癌の化学療法（HIGAN講義９）

Navigating Multidisciplinary Care With Immunotherapy in Esophageal/GEJ Cancer

Targeted Treatment Strategies: Innovative Approaches for the Management of Gastric Cancer

2023 Updates in Clinical Oncology – Gastrointestinal and Recent Advances in Pediatric Neuro-oncology

Innovative Approaches for the Management of Gastric Cancer: Q&A

Advanced Gastroesophageal Cancers: Maximizing the Benefits of Novel Immunotherapy Approaches

Clinical Trials Updates for Gastric Cancer Patients Webinar

2021 International Gastric Cancer Educational Symposium - Session 3